Japan plans to revise its guidelines on the drone delivery of medicines later this month, which would mark the first revision since they were established two years ago. Service providers are closely watching how they will be revised, with calls…
HOME > BUSINESS
BUSINESS
- Medinet Granted Patent on Cancer Antigen Peptide in 11 European Countries
September 12, 2011
- Helsinn Initiates Global PIII Program for Anamorelin
September 12, 2011
- Takara Bio to Supply Plasmid Vectors for iPS Cell Production to Kyoto University
September 12, 2011
- JAK Inhibitor May Be as Effective as Biologics at Lower Cost: Prof. Takeuchi of Keio University
September 12, 2011
- Tablet Terminals Effective for Changing Doctors’ Prescribing Behavior: M3
September 12, 2011
- MTPC Applies for DPP-4 Inhibitor Teneligliptin
September 12, 2011
- Toyama Chemical, Eisai Resubmit NDA for RA Treatment T-614
September 12, 2011
- Pfizer’s Novel NSCLC Treatment Crizotinib Receives Approval in US
September 12, 2011
- Bayer’s Alpharadin to Be Granted Fast Track Review Status from FDA
September 12, 2011
- PIII Trial for Type 2 Diabetes Treatment SYR-472 Started in Japan: Takeda
September 9, 2011
- Afinitor Approved for Pancreatic NET in Europe: Novartis
September 9, 2011
- Takeda to Invest ¥5 Bil. on Electric Power Facility
September 9, 2011
- Eisai to Accelerate Clinical Development with Milestone Payments, Signs Agreement on PIII Trials for Lenvatinib
September 8, 2011
- Eplerenone significantly Reduces Cardiovascular Death in High-Risk CHF Patients: Pfizer
September 7, 2011
- MTPC to Reorganize Its Subsidiary
September 7, 2011
- ASKA to Initiate Transparency GL Project on Full Scale in October
September 7, 2011
- Tarceva Approved for 1st-line in NSCLC: Roche
September 6, 2011
- Ogasawara to Become President, Ogawa to Step Down: RDKK
September 6, 2011
- Chugai Starts US-Japan PI Trials of Multiple In- Licenced Compounds from Roche
September 6, 2011
- Janssen Adds Precautions for CONCERTA for Administering to Patients Over 18
September 5, 2011
ページ
The healthcare supply chain in Japan, as in all major markets, consists of biopharmaceutical manufacturers selling to wholesalers who in turn sell to hospitals, clinics, and pharmacies, where the drugs are finally dispensed to patients. Each party ideally contributes value…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…